We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy
Dr. Tianyuan Wang, CEO of Clickmab, delivered a keynote at Guangzhou Laboratory, sharing the latest R&D practices and progress in AI-driven de novo antibody design, directed optimization, and the multi-agent platform.
On June 26, 2026, Dr. Tianyuan Wang, CEO of Clickmab, delivered a keynote at Guangzhou Laboratory titled "Epitope-Specific AI De Novo Antibody Design for Antibody Drug R&D: Principles, Current Applications, and Breakthrough Strategies". Drawing on the team's recent R&D practice, he highlighted the latest advances in AI-driven de novo antibody design, directed optimization, and the multi-agent platform.
Dr. Tianyuan Wang presenting on-site
Dr. Wang described how AI can generate antibodies for a specified epitope. The team has applied the approach to projects involving cytokine receptors and ADC targets, connecting computational design with binding assays and cell-based functional validation in an iterative workflow.
De Novo Antibody Design Case
Two antibody engineering optimization project cases were shared. One case focused on a GPCR agonistic nanobody, where AI optimization enhanced antibody activity. The other case targeted a CAR-T antibody, improving its specific binding to mutants and providing new ideas for improving the therapeutic window.
Antibody Optimization Cases
Antibody Optimization Cases 2
Affinity Maturation Case
Antibody Humanization Case
Dr. Wang identified a shortage of high-quality training data as a key limit on model generalization. Antibody–antigen complex structures are difficult and costly to obtain, restricting the data available to train and evaluate design models.
Clickmab is developing high-throughput data acquisition methods to build paired datasets of antibody sequences and antigen surface patches. The team plans to accumulate millions of high-quality patch–sequence pairs over the next two years to improve model performance and design success rates.
Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.